Advances in the biology and therapy of chronic myeloid leukemia: Proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop

Leukemia and Lymphoma

Volumn 54, Issue 6, 2013, Pages 1151-1158

  Van Etten, Richard A ^a   Mauro, Michael ^b   Radich, Jerald P ^c   Goldman, John M ^d   Saglio, Giuseppe ^e   Jamieson, Catriona ^f   Soverini, Simona ^g   Gambacorti Passerini, Carlo ^h   Hehlmann, Rüdiger ⁱ   Martinelli, Giovanni ^g   Perrotti, Danilo ^j   Scadden, David T ^k   Skorski, Tomasz ^l   Tefferi, Ayalew ^m   Mughal, Tariq I ⁿ  

^a TUFTS MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h University of Monza   (Italy)

ⁱ UNIVERSITY OF MANNHEIM   (Germany)

^j OHIO STATE UNIVERSITY   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l TEMPLE UNIVERSITY   (United States)

^m MAYO CLINIC   (United States)

ⁿ UNIVERSITY OF COLORADO   (United States)

more..

Author keywords

Chronic myelogenous leukemia; Dasatinib; Imatinib mesylate; Nilotinib; Tyrosine kinase inhibitor

Indexed keywords

BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; REBASTINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; BIOLOGICAL THERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER STEM CELL; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; LIVER DYSFUNCTION; MASS SPECTROMETRY; MYELOPROLIFERATIVE NEOPLASM; NEUTROPENIA; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; UNITED STATES; WORKSHOP;

ANIMALS; ANTINEOPLASTIC AGENTS; GENOMICS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; STEM CELL NICHE; TREATMENT OUTCOME;

EID: 84877787719     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.745524     Document Type: Review

References (62)

1. Duy C, Hurtz C, Shojaee S, et al . BCL6 enables Ph- acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 2011; 473 : 384 - 388.
2. Hurtz C, Hatzi K, Cerchietti L, et al . BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia . J Exp Med 2011; 208 : 2163 - 2174.
3. Zhang H, Li H, Xi HS, et al . HIF1alpha is required for survival maintenance of chronic myeloid leukemia stem cells . Blood 2012; 119 : 2595 - 2607.
4. H antschel O, W arsch W, E ckelhart E, et a l. B CR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia . Nat Chem Biol 2012; 8 : 285 - 293.
5. Walz C, Ahmed W, Lazarides K, et al . Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and Jak2V617F in mice . Blood 2012; 119 : 3550 - 3560.
6. Y uan H, W ang Z, L i L, et a l. A ctivation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis . Blood 2012; 119 : 1904 - 1914.
7. L i L, W ang L, Li L, et a l. A ctivation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib . Cancer Cell 2012; 21 : 266 - 281.
8. Goff D, S mith K M, S hih A, et a l. B CL2 splice isoform switching promotes leukemia stem cell survival and sensitivity to a novel pan BCL2 inhibitor . Blood 2011; 118 : Abstract 2735.
9. Shih A, Schairer A, Barrett CL, et al . Cycling toward leukemia stem cell elimination wtih a selective sonic hedgehog antagonist . Blood 2011; 118 : Abstract 3776.
10. Neviani P, Santhanam R, Oaks JJ, et al . FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia . J Clin Invest 2007; 117 : 2408 - 2421.
11. Oaks JJ, Mukhopadhyay A, Santhanam R, et al . FTY720 restores PP2A tumor suppressor activity in polycythemia vera CD34 - progenitors through inhibition of Jak2 V617F- and PI-3K © -dependent SET serine phosphorylation and enhancement of NOS-dependent PP2A tyrosine nitration. Blood 2011; 118: Abstract 2494.
12. Agarwal A, MacKenzie R, Oddo J, et al . A novel SET antagonist (OP449) is cytotoxic to CML cells, including the highly-resistant BCRABL T315I mutant, and demonstrates enhanced effi cacy in combination with ABL tyrosine kinase inhibitors . Blood 2011 ; 118 : Bstract 3757.
13. Nieborowska-Skorska M, Kopinski PK, Ray R, et al . Rac2-MRC-cIIIgenerated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors . Blood 2012; 119: 4253- 4263.
14. Bolton E, Schemionek M, Klein H-U, et al . Genomic instability originates from leukemia stem cells in a mouse model of CML-CP. Blood 2011; 118 : Abstract 445.
15. Slupianek A, Dasgupta Y, Ren SY, et al . Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia . Blood 2011; 118 : 1062 - 1068.
16. C ramer K, B olton E, N ieborowska-Skorska M, et a l. T argeting DNA repair gene, RAD52, induces exhaustion of the proliferating CMLCP leukemia stem cells carrying oxidative DNA damage . Blood 2011; 118 : Abstract 447.
17. R aaijmakers M H, M ukherjee S, G uo S, et a l. B one progenitor dysfunction induces myelodysplasia and secondary leukaemia . Nature 2010; 464 : 852 - 857.
18. Adams GB, Martin RP, Alley IR, et al . Therapeutic targeting of a stem cell niche . Nat Biotechnol 2007; 25 : 238 - 243.
19. Krause DS, Fulzele K, Catic A, et al . Parathyroid hormone-induced modulation of the bone marrow microenvironment reduces leukemic stem cells in murine chronic myelogenous-leukemia-like disease via a TGFbeta-dependent pathway . Blood 2011; 118 : Abstract 1670.
20. Yamamoto-Sugitani M, Kuroda J, Ashihara E, et al . Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia . Proc Natl Acad Sci USA 2011; 108 : 17468 - 17473.
21. Herrmann HD, Sadovnik I, Cerny-Reiterer S, et al . The leukemic stem cell (LSC) in Ph - CML is a CD34 - /CD38 - /Lin - cell that coexpresses dipeptidylpeptidase IV (CD26) and disrupts LSC-niche interactions by degrading the CXCR4 ligand SDF-1 〈 . Blood 2011; 118 : Abstract 961.
22. S overini S.De Benedittis C, G nani A, et a l. U ltra-deep amplicon sequencing using Roche 454 technology allows high sensitivity Bcr-Abl kinase domain mutation screening and anticipates emerging mutations leading to resistance to tyrosine kinase inhibitors in Philadelphiapositive leukemia patients . Blood 2011; 118 : Abstract 3775.
23. Ng KP, Hillmer AM, Chuah CT, et al . A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer . Nat Med 2012; 18: 521- 528.
24. Saglio G, Kim DW, Issaragrisil S, et al . Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia . N Engl J Med 2010; 362 : 2251 - 2259.
25. Kantarjian HM, Hochhaus A, Saglio G, et al . Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial . Lancet Oncol 2011; 12 : 841 - 851.
26. Saglio G, LeCoutre PD, Pasquini R, et al . Nilotinib versus imatinib in patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 36-month follow-up . Blood 2011; 118 : Abstract 452.
27. Larson RA, Hochhaus A, Hughes TP, et al . Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26: 2197- 2203.
28. Quintas-Cardama A, Kantarjian H, Luthra R, et al . Effi cacy of frontline nilotinib therapy in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in early chronic phase . Blood 2011; 118 : Abstract 454.
29. G ugliotta G, C astagnetti F, B reccia M, et a l. E arly CP CML, nilotinib 400 mg twice daily frontline: Beyond 3 years, results remain excellent and stable (a GIMEMA CML Working Party Trial) . Blood 2011; 118 : Abstract 2756.
30. Kantarjian H, Shah NP, Hochhaus A, et al . Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260- 2270.
31. Kantarjian HM, Shah NP, Cortes JE, et al . Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) . Blood 2012; 119 : 1123 - 1129.
32. C ortes J E, K im D W, K antarjian H M, et a l. B osutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial . J Clin Oncol 2012; 30 : 3486 - 3492.
33. Cortes JE, Maru A, De Souza C, et al . Bosutinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia - BELA trial: 24-month follow-up . Blood 2011; 118 : Abstract 455.
34. M ahon F X, R ea D, G uilhot J, et a l. D iscontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial . Lancet Oncol 2010; 11 : 1029 - 1035.
35. M ahon F X, R ea D, G uilhot J, et a l. D iscontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: Update results of the STIM study . Blood 2011; 118 : Abstract 603.
36. Rea D, Rousselot P, Nicolini F, et al . Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia (CML) patients (pts) with stable undetectable Bcr-Abl transcripts: Results from the French CML group (FILMC) . Blood 2011; 118 : Abstract 604.
37. Kumari A, Brendel C, Hochhaus A, et al . Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib . Blood 2012; 119 : 530 - 539.
38. Chomel JC, Sorel N, Guilhot J, et al . BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia . Blood 2012; 119 : 2964 - 2965.
39. Yeung D, Osborn M, White D, et al . Upfront imatinib therapy in CML patients with rapid switching to nilotinib for failure to achieve molecular targets or intolerance achieves high overall rates of molecular response and a low risk of progression - an update of the TIDEL-II trial. Blood 2011; 118 : Abstract 451.
40. Hughes TP, Lipton JH, Leber B, et al . Complete molecular response rate with nilotinib in patients with chronic myeloid leukemia in chronic phase without CMR after - 2 years on imatinib: Preliminary results from the randomized ENESTcmr trial of nilotinib 400 mg twice daily vs imatinib . Blood 2011; 118 : Abstract 606.
41. O ' Hare T, Shakespeare WC, Zhu X, et al . AP24534, a pan-BCRABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance . Cancer Cell 2009; 16 : 401 - 412.
42. Cortes JE, Kim DW, Pinilla-Ibarz J, et al . Initial fi ndings from the PACE trial: A pivotal phase 2 study of ponatinib in patients with CML and Ph - ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation . Blood 2011; 118 : Abstract 109.
43. C han W W, W ise S C, K aufman M D, et a l. C onformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036 . Cancer Cell 2011; 19 : 556 - 568.
44. Cortes JE, Talpaz M, Kantarjian H, et al . A phase 1 study of DCC-2036, a novel oral inhibitor of BCR-ABL kinase, in patients with Philadelphia chromosome positive (Ph -) leukemias including patients with T315I mutation . Blood 2011; 118 : Abstract 601.
45. Hughes T, Branford S . Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukemia . Blood Rev 2006; 20 : 29 - 41.
46. Hughes TP, Kaeda J, Branford S, et al . Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia . N Engl J Med 2003; 349 : 1423 - 1432.
47. Druker BJ, Guilhot F, O ' Brien SG, et al . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia . N Engl J Med 2006; 355 : 2408 - 2417.
48. Branford S, Seymour JF, Grigg A, et al . BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all fi rst-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria . Clin Cancer Res 2007; 13: 7080- 7085.
49. Jabbour E, Kantarjian H, O ' Brien S, et al . The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors . Blood 2011; 118 : 4541 - 4546.
50. Milojkovic D, Gerrard G, Paliompeis C, et al . The natural history of RTQ-PCR levels after the achievement of complete molecular remission (CMR): Implications for " stopping " studies . Blood 2011; 118: Abstract 605.
51. L atagliata R, B reccia M, C armosino I, et a l. C omplete cytogenetic response after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia. Blood 2011; 118 : Abstract 3783.
52. M arin D, I brahim A R, L ucas C, et a l. A ssessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors . J Clin Oncol 2012; 30 : 232 - 238.
53. Hanfstein B, Muller MC, Hehlmann R, et al . Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) . Leukemia 2012; 26 : 2096 - 2102.
54. Nicolini F, Hayette S, Labussiere H, et al . The month three major molecular response in chronic phase chronic myeloid leukemia on imatinib 400, nilotinib and dasatinib is a major prognostic factor for failure-free and progression-free survival . Blood 2011; 118 : Abstract 1684.
55. White DL, Saunders VA, Frede A, et al . The strategy of early nilotinib switch based on failure to achieve optimal molecular targets on imatinib may not overcome the negative impact of a low OCT-1 activity in de-novo CP-CML patients . Blood 2011; 118 : Abstract 1690.
56. Hochhaus A, Saglio G, Chuah C, et al . Dasatinib and imatinibinduced reductions in BCR-ABL transcript levels below 10% at 3 months are associated with improved responses in patients with newly diagnosed chronic myeloid leukemia in chronic phase: Analysis of molecular response kinetics in the DASISION trial . Blood 2011; 118 : Abstract 2767.
57. Marin D, Hedgley C, Clark RE, et al . Predictive value of early molecular response in patients with chronic myeloid leukemia treated with fi rst-line dasatinib . Blood 2012; 120 : 291 - 294.
58. Skorski T . BCR/ABL, DNA damage and DNA repair: Implications for new treatment concepts . Leuk Lymphoma 2008; 49 : 610 - 614.
59. Radich JP, Dai H, Mao M, et al . Gene expression changes associated with progression and response in chronic myeloid leukemia . Proc Natl Acad Sci USA 2006; 103 : 2794 - 2799.
60. Lange T, Ernst T, Pfi rrmann M, et al . Absolute quantifi cation of mutant T315I BCR-ABL transcripts at 6 months identifi es imatinib resistant CML patients with a low probability to achieve MMR after 12 months on second line tyrosine kinase therapy . Blood 2011; 118 : Abstract 1679.
61. P arker W T, H o M, S cott H S, et a l. M ultiple low level mutations identifi es imatinib resistant CML patients at risk of poor response to second-line inhibitor therapy, irrespective of the resistance profi le of the mutations . Blood 2011; 118 : Abstract 111.
62. O kimoto R A, V an Etten R A. N avigating the road toward optimal initial therapy for chronic myeloid leukemia . Curr Opin Hematol 2011; 18 : 89 - 97.